2-FDCK (2-Fluorodeschloro-ketamine)

2-FDCK – More information

2-Fl-2′-Oxo-PCM (also known as 2-Fluorodeschloroketamine, 2-FDCK, and inaccurately as 2-Fluroketamine, Fluoroketamine, and 2-FK) is a lesser-known novel dissociative substance of the arylcyclohexylamine class that produces dissociative, anesthetic, and hallucinogenic effects when administered. It is structurally related to arylcyclohexylamines like ketamine and deschloroketamine and is reported to produce similar effects.

Like other dissociative substances, it is primarily sought by recreational users for its ability to induce a hallucinogenic “out of body” state referred to as “dissociative anesthesia” (although the extent to which this occurs is highly dose-dependent). It has recently become available through online research chemical vendors where it is being sold as a designer drug replacement for ketamine.

There is very little information on the pharmacology, metabolism or toxicity of 2-fluorodeschloroketamine. It has an extremely brief history of human use. It is strongly advised to use harm reduction practices if using this substance.

clinical data

2-FDCK dosage table

2-FDCK effect progress

2-FDCK – Chemistry

2-Fluorodeschloroketamine, or 2-(2-Fluorophenyl)-2-methylamino-cyclohexanone, is classed as an arylcyclohexylamine drug. Arylcyclohexylamines drugs are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group. 2-FDCK contains a phenyl ring bonded to a cyclohexane ring substituted with a ketone group (cyclohexanone). An amino methyl chain (-N-CH₃) is bound to the adjacent alpha carbon (R₂) of the cyclohexanone ring. Additionally, the phenyl ring is substituted at R₂ with a fluorine group.

2-Fluorodescholoroketamine is a chiral molecule and is often produced as a racemate. Des- is a prefix used in chemistry to denote the absence of a functional group (in this case “chloro”) hence 2-FDCK is named for containing a fluorine substitution at its phenyl ring rather than the chlorine which is found in ketamine.

Toxicity

The toxicity and long-term health effects of recreational 2-FDCK use do not seem to have been studied in any scientific context, therefore the exact toxic dosage is unknown.
Furthermore,  2-FDCK has very little history of human usage.
Anecdotal evidence from people who have tried 2-FDCK within the community suggests  there aren’t any negative health effects attributed by simply trying this drug at low to moderate doses and using it sparingly (but nothing can be completely guaranteed).

Due to this, it is strongly recommended that one use harm reduction practices when using this drug.

2-FDCK – Abuse

As with other NMDA receptor antagonists, the chronic use of 2-Fluorodeschloroketamine can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 2-FDCK develops with prolonged and repeated use. This results in increasingly large doses to achieve the same effects. Moreover, it takes about 3 – 7 days for the tolerance to be reduced to half, and 1 – 2 weeks to be back at baseline (in the absence of further consumption).
2-Fluorodeschloroketamine presents cross-tolerance with all dissociatives, meaning that after the consumption of 2-Fluorodeschloroketamine all dissociatives will have a reduced effect.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 2-Fluorodeschloroketamine seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine but to a lesser extent. This is because 2-Fluorodeschloroketamine is a little more potent than ketamine, meaning that less of the drug needs to be consumed. ketamine-induced cystitis symptoms can become extremely serious and can be described as:

However, all of these,  can easily be avoided by simply not using 2-Fluorodeschloroketamine on a daily, and even weekly basis and manually limiting one’s usage of the substance.